![](https://www.primebusiness.africa/wp-content/uploads/2022/11/novartis-and-medicines-for-malaria-venture-announce-decision-to-move-to-phase-3-study-for-novel-ganaplacide-lumefantrine-sdf-combination-in-adults-and-children-with-malaria.png)
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
· Novartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria · This novel combination also contains an optimized formulation of
Follow Us